Genenta Science SpA logo

Genenta Science SpANASDAQ: GNTA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Italy

IPO:

15 December 2021

Next earnings report:

25 November 2024

Last dividends:

N/A

Next dividends:

N/A
$85.96 M
-60%vs. 3y high
43%vs. sector
-vs. 3y high
-vs. sector
-69%vs. 3y high
80%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Wed, 20 Nov 2024 21:00:00 GMT
$4.70-$0.24(-4.86%)

Dividend

No data over the past 3 years
No data over the past 3 years
No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

GNTA Latest News

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
globenewswire.com23 October 2024 Sentiment: POSITIVE

Genenta's CEO to present at the U.S. Senate, Washington D.C.at the meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatl

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
globenewswire.com02 October 2024 Sentiment: POSITIVE

MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), marking a significant expansion of the potential applications for Genenta's flagship product, Temferon™. This approval by AIFA is in line with the standards that are harmonized across European regulatory frameworks established by the European Medicines Agency (EMA).

Genenta to Present at Upcoming Scientific and Investor Conferences
GlobeNewsWire06 September 2023 Sentiment: POSITIVE

MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences.

What type of business is Genenta Science SpA?

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

What sector is Genenta Science SpA in?

Genenta Science SpA is in the Healthcare sector

What industry is Genenta Science SpA in?

Genenta Science SpA is in the Biotechnology industry

What country is Genenta Science SpA from?

Genenta Science SpA is headquartered in Italy

When did Genenta Science SpA go public?

Genenta Science SpA initial public offering (IPO) was on 15 December 2021

What is Genenta Science SpA website?

https://www.genenta.com

Is Genenta Science SpA in the S&P 500?

No, Genenta Science SpA is not included in the S&P 500 index

Is Genenta Science SpA in the NASDAQ 100?

No, Genenta Science SpA is not included in the NASDAQ 100 index

Is Genenta Science SpA in the Dow Jones?

No, Genenta Science SpA is not included in the Dow Jones index

When was Genenta Science SpA the previous earnings report?

No data

When does Genenta Science SpA earnings report?

The next expected earnings date for Genenta Science SpA is 25 November 2024